Myriad Genetics Inc. (MYGN)
NASDAQ: MYGNHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MYGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $523.74M
- EPS (TTM)
- -$1.35
- Dividend yield
- None
- Ex-dividend date
- Jul 1, 2009
- 52-week range
- 2.74 – 8.09
- Day range
- 5.31 – 5.57
- Volume / Avg
- 1.25M / 2.26M
- Beta
- —
- Shares outstanding
- 95.92M
52-week range
MYGN stock today
Myriad Genetics (MYGN) closed at $5.46 on Nov 20, down 1.44% (-$0.08), versus the S&P 500's 3.70% decline. Shares are 32.5% below their 52-week high of $8.09, set on Nov 25, 2025 and 99.3% above the 52-week low of $2.74, in the middle of the past year's range. MYGN is down 11.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 26.0%.
Myriad Genetics has posted a net loss over the last twelve months (EPS of -$1.35), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Myriad Genetics
Company profileMyriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Samraat S. Raha
- Headquarters
- Salt Lake City, UT
- Employees
- 2,700
- IPO year
- 1995
- Website
- myriad.com
Financial highlights
Full financialsIn fiscal 2025, Myriad Genetics generated $824.5 million in revenue, down 1.6% from fiscal 2024, its first annual decline since 2022. Myriad Genetics reported a net loss of $365.9 million, compared with a loss of $127.3 million a year earlier. Gross margin was 69.9% (flat year over year) and operating margin -47.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $824.50M | $837.60M | $753.20M | $678.40M | $690.60M |
| Growth | -1.56% | +11.21% | +11.03% | -1.77% | +23.96% |
| Net income | $-365.90M | $-127.30M | $-263.30M | $-112.00M | $-27.20M |
| EPS (diluted) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 |
Analyst forecast
ForecastConsensus (9 analysts)
hold
Avg. price target
$5.90+8.06%
- Strong buy 0
- Buy 1
- Hold 6
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.13 vs $-0.25
- Surprise
- +48.00%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $1.75
- Ex-dividend date
- Jul 1, 2009
MYGN news
All MYGN news- Myriad Genetics Targets Faster Testing Turnaround With Expanded SRL PartnershipNasdaqMYGN, LEN.B
- Myriad Genetics Expands SRL Partnership in Japan to Support Future GrowthGlobeNewswire
- Myriad Genetics Consensus Price Target Increased by 21.17% to $5.55Nasdaq
- Myriad Genetics, Inc. Approves Retention Option Awards for Executive Officers on November 6, 2026NasdaqMYGN, LEN.B
- Myriad Genetics Raises FY26 Revenue Outlook Midpoint; Agrees To Sell Prenatal Health BusinessNasdaqMYGN, ET
- Myriad Genetics, Inc. Detects Unauthorized IT Network Access on November 2, 2026Nasdaq
- Myriad Genetics Reports Third Quarter 2026 Financial Results and Announces Agreement to Sell Prenatal Health BusinessNasdaq
- Myriad Genetics Non-GAAP EPS of -$0.11 beats by $0.09, revenue of $202.7M beats by $11.37MSeeking Alpha
Myriad Genetics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QDELQuidelOrtho Corporation | 8.32 | -6.73% | $570.86M | vs MYGN |
| QUITAchieve Life Sciences Inc. | 5.56 | -5.28% | $573.25M | vs MYGN |
| TKNOAlpha Teknova Inc. | 7.63 | -2.30% | $479.95M | vs MYGN |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs MYGN |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs MYGN |
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs MYGN |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs MYGN |
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs MYGN |
Indexes, lists and sector
Myriad Genetics stock FAQ
What is Myriad Genetics's stock price today?
MYGN last traded at $5.46 as of Nov 20, 4:00 PM EST, down 1.44% on the day. Prices are delayed at least 15 minutes.
Does Myriad Genetics pay a dividend?
Yes. Myriad Genetics pays $0.00 per share annually. The most recent dividend of $1.75 had an ex-dividend date of Jul 1, 2009.
Who is Myriad Genetics's CEO?
Mr. Samraat S. Raha is the chief executive officer of Myriad Genetics Inc., which has about 2,700 employees.
Has MYGN ever split its stock?
Yes. The most recent MYGN stock split was a 2-for-1 split on Mar 26, 2009, one of 2 splits on record.
What is the MYGN 52-week high?
The 52-week high for MYGN is $8.09 and the 52-week low is $2.74. The stock is currently 32.5% below its high.